Home / Transcripts / Ashland Inc. (ASH) · April 29, 2026

Ashland Inc. (ASH) Earnings Call Transcript

April 29, 2026

New York Stock Exchange US Materials Chemicals earnings 76 min

Earnings Call Speaker Segments

Sandy Klugman executive
#1

Thanks. Good day, everyone, and welcome to the earnings conference call and webcast for Ashland's second quarter of fiscal 2026. I'm Sandy Klugman, serving as Director of Investor Relations at Ashland. With me today are Guillermo Novo, our Chair and CEO; William Whitaker, our CFO; and the leaders of our business units: Alessandra Assis for Life Sciences and Intermediates; Jim Minicucci for Personal Care; and Dago Caceres for Specialty Additives. Be aware that slides will be shown during this call. We invite you to view the webcast materials, which can be found at ashland.com in the Investor Relations section. Kindly go to Slide 2. Just a reminder, this presentation includes forward-looking statements about our fiscal 2026 outlook and other topics, as laid out on Slide 2 and in our Form 10-Q. Such statements carry risks and uncertainties that might lead future outcomes to vary materially from the projections shared today. We consider these statements to rest on reasonable assumptions, though we cannot guarantee that these expectations will come to pass. We'll also mention some adjusted financial metrics, actual and projected, which are non-GAAP measures. These adjusted figures are provided to give you more perspective on how our business is performing on an ongoing basis. Reconciliations to GAAP can be found on our website and in the appendix of these slides. I'll now pass the call to Guillermo for his opening remarks.

Guillermo Novo executive
#2

Appreciate it, Sandy, and hello to everybody on the call. I'll begin by giving a quick look at how we did in Q2, and after that William will take you through the numbers and our guidance, and then the team will provide a closer review by business unit. If you'd go to Slide 5. Taken as a whole, our Q2 results show resilient underlying commercial performance against stable demand conditions, with pricing and portfolio mix action still a central focus company-wide. Life Sciences turned in steady results, helped by resilient pharma demand. Injectables, tablet coatings and high-purity excipients kept driving growth, which marked a fourth straight quarter of volume gains. Momentum across our innovate and globalized pillars remains strong, with differentiated new product introductions continuing to be adopted. Personal Care produced broad-based portfolio growth, fueled by strong volume gains and execution in biofunctional actives, care ingredients and microbial protection. Biofunctional actives posted robust double-digit growth versus the prior year, while microbial protection kept picking up share after our globalized investments. Specialty Additives dealt with a mixed market environment. Coatings volumes rose year-over-year on share gains and new product traction, while construction sales stayed lower, which reflects deliberate portfolio mix actions and demand that was slightly softer. Overall results came back to flat year-over-year, an important step forward since we have not yet fully lapped last year's China impact. Intermediates faced a stable but trough level environment, with results hurt by both the commercial and operating effects of the Calvert City outage. The team will go into more detail later, but operational performance took a hit from specific issues in the quarter, all of them internal and not a reflection of underlying demand trends. Even with these headwinds, commercial execution was solid across much of the portfolio, and demand trends in Q3 continue to look encouraging. If you'd go to Slide 6. I'll now take you through our Q2 results, which show disciplined execution across the portfolio in a mixed market environment. Teams stayed focused on cost control, operating discipline and customer service while working through operational headwinds in the quarter. Structural actions taken over the past several years keep supporting the underlying economics of the business, even though near-term performance came under pressure from temporary execution challenges. Working capital was a key strength in the quarter, driving strong operating cash flow and reinforcing our focus on cash discipline. Across the portfolio, the quarter showed resilient underlying performance and continued progress in strengthening the business foundation, with demand conditions broadly stable across the portfolio and margin pressure driven mainly by specific operational issues rather than weakness in end markets. If you'd go to Slide 7. First, our consumer-focused businesses, principally Life Science and Personal Care, keep providing stability, supported by resilient end market demand. Second, innovation and globalization initiatives are gaining traction, with momentum accelerating in higher-value applications across the portfolio. Innovation has already surpassed our full year target after 2 quarters, which reflects strong pipeline execution and commercialization. Third, the structural steps we took in earlier periods are now built into how the business runs, which strengthens margin durability and puts the portfolio in a position to gain once operating conditions return to normal. Our teams stay focused on disciplined execution and targeted corrective measures. Before I hand things to William, I want to highlight 3 themes for this quarter: resilient demand in consumer-focused areas, momentum that is accelerating in innovation and globalization, and a continued commitment to improving execution. At this point I would like to pass the call to William so he can give a more detailed review of our second quarter financial performance. William?

William Whitaker executive
#3

Thank you, Guillermo. Let's move on to Slide 9. For the second quarter, we posted sales of $482 million, which is a 1% increase compared to the same period last year, showing resilient demand across a large portion of our portfolio. Overall volumes held fairly steady, as growth in Personal Care made up for weakness in Intermediates, while Life Sciences turned in a consistent performance. Pricing was down slightly from a year earlier, mainly due to carryover effects from earlier pricing moves that supported targeted efforts to gain share across most segments. Currency movements gave us a significant boost, adding about $16 million, or 3%, to reported sales. Adjusted EBITDA came in at $98 million, a 9% drop from the prior year, which includes roughly $10 million in previously announced temporary impacts, such as the Calvert City start-up delay and weather-related operational interruptions during the quarter. If you set aside those specific items, the underlying results showed softer pricing, which was balanced by strict cost management and favorable foreign exchange, in line with the resilient trends we're seeing throughout the portfolio. As we mentioned before, Calvert City weighed on second quarter results. The repairs have been finished and the plant is running again. Our adjusted EBITDA margin stood at about 20%, a decrease of 220 basis points from last year, mostly due to those temporary operational disruptions. Adjusted EPS, not counting intangible amortization, reached $0.91, an 8% decline year-over-year, matching the drop in EBITDA. Cash generation and conversion were clear highlights this quarter. Operating cash flow was $50 million, compared to $9 million a year ago, thanks to careful working capital management, including significant inventory cuts. Ongoing free cash flow was $29 million, showing strong conversion from working capital gains and lower capital spending; we closed the quarter with roughly $939 million in total available liquidity and net debt slightly above $1 billion, putting net leverage at about 2.7x. Our balance sheet stays solid, giving us room to support operations, put money into strategic priorities, and keep capital allocation disciplined. With that, I'll hand things over to our business unit leaders to dive deeper into segment performance. Alessandra, the floor is yours for Life Sciences.

Alessandra Assis executive
#4

Thanks, William. Morning, everybody. If you could go to Slide 10, that's Life Sciences. Life Sciences sales came in at $172 million, which was flat versus a year ago. What we're seeing there is resilient demand from pharma, partly offset by softness in some non-pharma end markets and a bit of pricing pressure. Pharma grew low single digits, and that's now a fourth quarter in a row, helped by strength in differentiated cellulose excipients, injectables, and tablet coatings. Away from pharma, nutrition and the other non-pharma markets stayed softer, and that's really about customer order timing, not any deterioration in the underlying market. Pricing was down modestly versus last year, mostly carryover from actions taken in prior periods, while sequentially it held steady. FX added roughly $6 million to sales in the quarter. On our globalized initiatives, Injectables kept growing quarter over quarter and posted a record second quarter. The lead indicators look positive — sales pipeline, new product uptake, and new orders — which points to continued momentum in this high-margin segment. <<inaudible>> kept up its double-digit growth trajectory versus the prior year, which is fueling capacity release initiatives. Now to innovation. Growth here came from expanding adoption of low nitride oral solid dosage excipients plus high-purity injectable and bioprocessing products. New product success in this segment reinforced Echelon's differentiation in regulated, high-value markets, fully aligned with our growth strategy. As we look ahead, we've set up the second half of the year for multiple new product launches across oral solid dose, injectables, and Crop Care, which supports sustained growth and portfolio renewal. These initiatives keep reinforcing portfolio differentiation and long-term growth opportunities. Now profitability. Adjusted EBITDA was $50 million, down 11% versus a year ago. Adjusted EBITDA margin was 29%, and that reflects the combined impact of modestly lower pricing and higher costs, including about $5 million of weather-related disruption and Calvert City start-up delays in the quarter. Those headwinds were partly offset by favorable mix, disciplined execution, and FX, which added approximately $3 million to EBITDA. Importantly, underlying pharma demand remains resilient, and the pricing actions we recently announced are now being implemented across the portfolio. Life Sciences continues to benefit from durable end market fundamentals, strong customer engagement, and sustained momentum across our Innovate and globalized pillars. Please turn to Slide 11, Intermediates. Intermediates operated in a challenging but stable trough market environment, consistent with what we expected going into fiscal year 2026. Demand conditions remain stable, with sales and pricing at trough levels across the BDO value chain. Sales were $35 million, down 5% versus last year, reflecting continued pressure across the BDO value chain and commercial and operating impacts related to the Calvert City outage. Merchant sales were $26 million compared to $27 million last year, as our relatively steady volumes were partly offset by modest pricing pressure and disciplined commercial actions, including controlled merchant activity. Captive BDO sales were down approximately $1 million year over year, primarily reflecting the Calvert City impacts in the quarter. FX gave a modest $1 million benefit to sales in the quarter. Now profitability. Adjusted EBITDA was $5 million, up from $2 million in the prior year quarter. The gain came from keeping tight control on costs and making advantageous moves on manufacturing inputs, and those benefits outweighed both the effects tied to Calvert City and the continuing strain throughout the BDO value chain. At this point, I'll hand things over to Jim so he can cover Personal Care.

Jim Minicucci executive
#5

Thanks, Alessandra. Now I'll walk through what happened in Personal Care. If you'd go to Slide 12, that covers Personal Care. Our Personal Care segment turned in resilient performance, backed by demand that was broad-based along with solid execution throughout the portfolio. Sales came in at $150 million, which is a 3% increase versus a year ago, or 4% on a comparable basis, and that was powered by gains in all 3 business lines. Biofunctional actives posted yet another quarter of double-digit growth, helped by ongoing uptake of <<inaudible>> plus customer expansions in Europe and North America. Microbial Protection saw robust growth spanning the portfolio and geographies, fueled by new customer wins along with continued share gains. In Care Ingredients, the portfolio stayed resilient, with strong growth in hair and skin care categories, especially across Asia Pacific and Latin America. The customer-specific outages we flagged last quarter have come back to more normalized levels now. Foreign exchange added roughly $5 million to sales in the quarter. Moving to innovation. Biofunctional Actives just introduced Essernonite, our 2026 flagship ingredient. Essernonite goes after key skin longevity markers and picked up an industry award at the In-Cosmetics Global event earlier this month. Care Ingredients rolled out a new hair care conditioning polymer built on our VR technology, and it's already seeing customer adoption. All told, Personal Care keeps benefiting from strong momentum across our globalize and innovate platforms, which reinforces growth in consumer-focused applications. Now on profitability. Adjusted EBITDA reached $43 million, versus $44 million in the same quarter last year. That modest decrease came from operational outages tied to weather-related events, which were largely offset by volume growth and mix. Adjusted EBITDA margin stood at approximately 29%, which shows the portfolio's strength and the payoff from ongoing commercial and productivity efforts. Foreign exchange added roughly $2 million to EBITDA; to sum up, Personal Care achieved robust sales growth across all 3 business lines, showing strong margin resilience, disciplined execution and meaningful progress on its innovate and globalize initiatives; with that, I'll hand the call to Dago to go over the results of Specialty Additives.

Dago Caceres executive
#6

Thanks, Jim. Let's move to Slide 13. In Q2, Specialty Additives faced uneven demand, with results differing across regions and end markets. On the whole, our performance showed disciplined commercial execution, with focused pricing moves helping us gain share, alongside certain operational challenges. Sales came in at $134 million, unchanged from a year earlier, as volume growth for a second straight quarter was mostly canceled out by softer pricing and by comparisons against a tough prior-year period following share losses in China. Looking at the segments: Architectural Coatings went back to growth versus last year, aided by share gains and momentum from new products. Volume trends improved compared with earlier quarters as commercial efforts built momentum, while underlying demand was broadly flat, with regional variation continuing. Construction volumes fell, which reflects intentional portfolio mix management tied to network optimization as well as fairly subdued end market demand. Other end markets were mixed, with volume growth in Performance Specialties offset by weaker energy demand linked to customer-specific effects in the Middle East. Pricing was down slightly versus last year, reflecting targeted opportunities to gain share. Foreign exchange added about $4 million to reported sales. Now on profitability: Adjusted EBITDA was $16 million, compared with $26 million in the same quarter last year. Adjusted EBITDA margin was 11.9%, reflecting softer pricing and higher manufacturing-related costs, including roughly $2 million from weather-related disruptions, a discrete bad debt reserve tied to a Middle East energy customer, and productivity challenges related to the Hopewell scale-up, particularly the HEC scale-up. We have maintained product quality and customer service levels, and reaching profitable scale remains a key operational priority. Although near-term performance has been affected, these steps are expected to improve long-term reliability and cost efficiency across our cellulosics network. All other sites continue to run reliably, and our global network supported uninterrupted customer supply. Overall, we remain focused on targeted actions to improve operational performance, strengthen cost control, and advance differentiation across the applications, positioning the business to benefit as market conditions normalize; with that, I'll hand the call back to William.

William Whitaker executive
#7

Thank you, Dago. Let's move to Slide 15. In light of what's recently unfolded geopolitically in the Middle East, I'd like to take a moment to explain where Ashland stands in this kind of setting. Beginning with exposure: our direct exposure is both limited and manageable. Around 5% of total sales come from the Middle East and North Africa, mostly in Turkey and Egypt, and since we have no manufacturing footprint in that region, operational risk is significantly reduced. On the cost side, Ashland holds a structural advantage; throughout our portfolio, we depend less on petrochemical and energy-intensive feedstocks. About 15% of revenue depends on inputs that are energy-intensive, and most of those we bring in from North America. That helps keep cost swings smaller and margins steadier when energy prices move around. The team keeps advancing pricing measures meant to offset rising costs. Since additives represent only a modest share of what our customers pay overall, we expect to be able to pass these increases through. On the demand side, visibility is still solid, helped by a robust order book and a mix weighted toward consumer-facing end markets that hold up well, such as pharma and personal care. Finally, based on what we learned from earlier disruptions, we believe customers will place growing value on supply security. Persistent geopolitical turmoil, anti-dumping measures, and companies rethinking reliance on a single region are all making the case stronger for dependable, diversified supply networks — which puts Ashland in a favored position as a partner for vital applications. Taking everything into account, even though conditions keep shifting, our modest exposure, favorable cost position, steady demand patterns, and trustworthy supply chain leave us well equipped to handle turbulence. Now please go to Slide 16. I want to take a few minutes to discuss our execute agenda, zeroing in on manufacturing — the difficulties we ran into at Hopewell, where we stand on the wider commitment, and the way this connects to the cost savings goals we've set for the longer term. Let's begin with Hopewell. Our HEC scale-up moved ahead more slowly than we had intended, and that held back second quarter performance. To build on what Dago said, we've kept up both the quality of our products and the service we give customers. That said, productivity, yield and cost performance didn't scale up the way we thought they would. These are internal execution problems, and we've responded with focused measures — tightening how we run operations, putting more leadership attention on the site, and pushing ahead on particular technical work streams. Productivity is still under where we want it, but things have leveled off, and we're seeing improvement from one period to the next. We'll keep taking these targeted steps, even though it will take time before the financial gains show up in our results. One thing worth stressing: what happened at Hopewell doesn't undermine the strategic case for consolidating. That site is still essential if we're going to simplify the network and bring down the structural cost base of our cellulosics platform. When you look beyond Hopewell, the work we're doing to optimize manufacturing keeps moving forward just as we anticipated. Our VP&D efforts and the steps to consolidate smaller plants are still on schedule, and the gains from those will land mostly in the back half of fiscal 2026. Because things at Hopewell have taken longer than planned, the benefit we expected from manufacturing optimization in fiscal 2026 is now about $10 million to $12 million lower. What that shows is a delay in when we capture the value, not a smaller opportunity underneath. Zooming out, what we're aiming for with manufacturing optimization over the long run is unchanged. We still look for $50 million to $55 million in yearly cost savings that can be sustained, and there's an opportunity to reach about $60 million once volumes in China recover. Execution continues to be a key strategic pillar for us, centered on making the footprint simpler, boosting reliability, and enhancing our cost competitiveness. Near-term execution has been uneven, but the steps we're taking are meant to guarantee we capture the program's full value over time. In a moment, I'll explain how that feeds into what we expect and our outlook for the rest of fiscal 2026. If you'd go to Slide 17. Now I want to give you a quick progress report on our Globalize and Innovate platforms. Let's begin with Globalize. Its performance has picked up pace versus a year ago, with incremental contribution rising by about $8 million to $11 million fiscal year-to-date. In the quarter, Globalized businesses posted double-digit growth compared with last year, and incremental sales so far are running ahead of plan, which shows the ongoing benefit from investments we made previously in our regions. Now for Innovate, where the momentum has been even more pronounced. After only 2 quarters, Innovate has already surpassed its target for the full year, which speaks to faster commercialization throughout the portfolio. Results have been driven by enduring strength in high-purity pharma excipients, with growing contributions coming from GLP-1-related applications. During the quarter, Innovate generated roughly $10 million in incremental sales, which pushed us beyond our initial $15 million goal for the full year; that demonstrates both the strength and the depth of our innovation pipeline, especially in <<inaudible>>, along with successful launches of new products in other areas of the portfolio. Given the progress so far, strong execution on both platforms bolsters our confidence that we will hit our fiscal 2026 combined revenue commitment of $35 million from Globalize and Innovate. If you'd turn to Slide 18. I'll take you through our revised fiscal 2026 outlook now, which incorporates present operating conditions and a cautious stance on near-term execution while keeping faith in the portfolio's fundamental strength; for fiscal 2026, here's how we're updating guidance: On sales, $1.835 billion to $1.87 billion, and adjusted EBITDA between $385 million and $400 million. We also anticipate adjusted EPS growth in the mid-single to high single-digit range and ongoing free cash flow conversion at roughly 50% of adjusted EBITDA. This revised outlook captures weaker energy-related demand connected to the Middle East conflict, lower EV-driven demand, and productivity at Hopewell that has been slower than anticipated. Partly offsetting that are resilient demand in core end markets, continuing price actions, and sustained growth from our Globalize and Innovate platforms; furthermore, the key assumptions behind this outlook include Life Sciences and Personal Care staying resilient, backed by stable end market fundamentals, ongoing portfolio progress, and encouraging early demand trends in the third quarter. Specialty Additives and Intermediates markets are holding steady at trough levels, and any recovery in coatings is likely to be gradual and uneven across regions. Raw material and logistics costs are moving upward, driven by geopolitical volatility, though recent pricing actions should counter those effects. Performance is still weighted toward the second half, in line with historical seasonality. Taking all of that into account, we feel it makes sense to stay cautious while we keep running production, inventory and free cash flow in a disciplined way. So with that, I'll hand the call over to Guillermo now so he can go through our technology platforms and offer a few final remarks before we take questions. Guillermo?

Guillermo Novo executive
#8

Thanks, William. For Ashland, innovation continues to be a key engine behind long-term value creation, and what we're achieving in fiscal 2026 underscores just how robust our pipeline is. On Slide 19, we show 3 innovation platforms that illustrate the way we turn science into scalable, differentiated growth opportunities spanning a range of end markets. What matters is that these are scalable technology foundations, backed by collaboration with customers, regulatory advancement and well-defined routes to commercialization. Let's begin with transformed vegetable oil. This platform keeps advancing toward early commercialization. Trials with customers are moving forward in crop care, regulatory milestones are being reached, and TVO-based solutions are broadening into personal care, coatings and industrial applications. Now to super wedding agents. Customer input remains very positive, particularly when it comes to personal care. This PFAS-free, silicon-free technology was first created inside Specialty Additives, and now it's spreading into a variety of end markets. And finally, bioresorbable polymers continue gaining traction in high-value medical uses like long-acting injectables and medical devices. Beyond these platforms, we're continuing to advance nearby innovation efforts that reach into personal care and coatings—things like new multifunctional starches, pH neutralizers and next-generation rheology solutions—with several worldwide launches set for fiscal 2026, alongside early regulatory headway that supports wider commercialization. Taken as a whole, these platforms demonstrate Ashland's ability to convert science into scalable growth, combining robust technical strengths, expanding global manufacturing and strong customer ties to support value creation over the long run. Let's move to Slide 20. As we look forward, let me quickly outline the leadership priorities guiding what we do while we strengthen the company's foundation and set Ashland up for lasting performance past 2026. Our expectations for the full year reflect both the underlying strength of our portfolio and the fact that operating performance this year has fallen short of our standard. Even though the market environment remains mixed, the fundamentals of the business continue to deliver resilience. Specific internal manufacturing challenges weighed on second quarter results; those issues are disappointing, but they are internal and within our control, and addressing them ranks as a top priority for the leadership team. We are taking targeted, disciplined steps to improve operational reliability, cost performance and consistency of execution. At the same time, a number of pieces of our plan continue to move ahead. Like William pointed out, the momentum behind innovation and globalization is still solid. Generating cash and keeping the balance sheet disciplined remain priorities, and they help us stay resilient when the macro environment is choppy. We're also simplifying the portfolio and taking structural steps, which are shoring up the base for better results as execution settles down. Looking ahead, we know exactly what we're focused on. On the operational side: run things safely and dependably, with steady customer service as the goal; get manufacturing execution stabilized and improved; carry out pricing moves so raw material inflation is offset, while actively handling supply chain swings to build greater resilience; and turn the innovation momentum into commercial wins by leveraging our global platforms. Fiscal 2026 is a year for making the foundation stronger. Although our recent manufacturing results haven't met what we anticipated, the approach is still the right one, and everything we're doing centers on getting back to fulfilling what we promised. With a sharper portfolio, end markets that hold up well, and a well-defined operational plan, we're set up to handle the obstacles right now while working toward stronger results in fiscal 2027. I'd like to express my gratitude to everyone at Ashland for staying dedicated through a tough stretch. I'm also grateful to our shareholders for the way they keep engaging with us and backing us. Operator, could you please open the line so we can take questions?

Josh Spector analyst
#9

Could you expand a bit more on the interplay between pricing and costs? My sense is that during earlier energy upcycles, your company came out ahead thanks to certain backward-integrated operations, and the only question was when prices would align. Yet instead of lifting your sales outlook because of stronger pricing, you reduced it for a few separate reasons. So I'd like to hear more about how you see this unfolding across the back half of the year, whether this is something that stretches out longer, or whether my framing is simply off base.

Executive executive
#10

Josh, thanks for raising that — it's an essential topic given current conditions. I'll start with pricing, then move to the changes we made to portions of the guidance. On pricing, to begin with, we are taking action. Every unit has announced moves and is carrying them out, reflecting varying costs across geographies; we're implementing this market by market and line by line. As we did in 2022, our pace is fast. The cost share we represent for our buyers isn't large. Our exposure to petrochemicals is comparatively limited, so the total increases needed to offset costs aren't especially big; the sooner we act, the sooner we're out of our customers' way, since they face larger issues requiring attention. That's what we're aiming for. So we're proceeding on that front, and benefits have already begun appearing, with more set to reach our results during this month and in the months ahead. To be clear, we're also pursuing both outright price hikes and surcharges, depending on the contracts and what each situation requires. The market, I believe, grasps these dynamics. Naturally, timing, size and similar matters require a back-and-forth with buyers, yet our progress is quite strong. Turning to our guidance: conditions today are highly uncertain on many fronts, so cutting the top end of the sales forecast stemmed largely from factors already visible to us. Within Energy & Resources, which represents only a modest slice of our total exposure, we do hold certain operations in the Middle East, and those are declining in sales terms; we also encountered some credit troubles, though we expect recovery down the road. For the moment, given these conditions, the effect is modest. Beyond that, we're witnessing numerous postponements among EV projects tied to intermediates. Those are essentially the causes; where pricing is concerned, the direction is favorable. And we didn't raise it or take that into account, but the macro market still has plenty of uncertainty. The main things we're watching, I'd say, are whether demand begins to recover in North America — coatings, for instance. In North America and Europe, no improvement is showing up. So we'd rather stay cautious there. That's why I'd treat the pricing dynamic as more of an upside within these figures.

Josh Spector analyst
#11

All right, that's useful. Perhaps briefly on Life Sciences. I believe you mentioned the decline observed in Nutrition and discussed the timing of customer orders. And I realize that's fairly minor, but can you see that recovering? Since I think most of your remarks generally had demand being more resilient throughout Life Science and Personal Care, and that's perhaps the single exception to that pattern.

Executive executive
#12

Yeah. No, we're aiming to be open regarding the individual segments. I'll have Alessandra weigh in. But on the whole, I'd say Life Science and Personal Care are trending favorably. We're not saying, for instance, that we've cycled through everything, but to put it plainly, with Personal Care, for instance, we did record some sales during the prior year. So growth is in fact somewhat higher; so on the whole, every segment is performing fairly nicely; but Alessandro, if you'd like to speak — it isn't a major concern.

Alessandra Assis executive
#13

Yeah. Let me say a few things regarding nutrition outside of pharma. As we discussed, we've recently landed some wins, and the commercial work currently underway does back the expansion we're forecasting for Q3 and Q4. Josh, this comes down to timing. On Nutrition, a few orders shifted in terms of when they landed, yet our confidence remains solid regarding the wins we're observing and the commercial work. It's simply a matter of timing, though we do see traction getting better.

Kevin Estok analyst
#14

Kevin Estock here, filling in for Laurence. Regarding the updated guidance—$385 million to $400 million in EBITDA—could you lay out what has to break our way to reach that upper bound, especially when it comes to operations and realizing pricing?

Executive executive
#15

Like we mentioned in the other call, price represents potential upside. That means the combined effect of price along with the macroeconomic demand picture, and it's largely within Specialty Additives and Intermediates. There's room for improvement there. Those two items are the major ones, and given the uncertainty, we're choosing to be cautious and conservative by leaving them out right now. We're also paying attention to what our customers tell us. When you consider coatings clients across North America and Europe, not a single one—everyone is acting more cautiously. So I believe it's wiser to stay conservative and then outperform if those markets strengthen. Let me add a bit more: when you consider the guidance range, the sales line accounts for most of it. At the bottom end, with low single-digit year-over-year growth, pricing activity largely drives that, which naturally suggests volumes are roughly flat otherwise; at the top end, though, you're looking at roughly a 6% to 7% sales growth rate, split evenly between volume and price. On the volume side, thanks to the team, we've had a really solid beginning on Globalize and innovate, and we anticipate that continuing; so delivery growth beyond the Global and Innovate is what lifts you to the higher end.

Jeff Zekauskas analyst
#16

When you add together every one-off item within Specialty Additives during the quarter, what did that come to? Also, do you anticipate that Specialty Additives operating income will increase in Q3?

Executive executive
#17

Jeff, there are 2 points I'd make that fit with what you're asking, though I'll take it a bit wider. The larger impact so far this year came from Calvert City, which hit the entire business, primarily life science plus personal care. That involved equipment failure and downtime. We were simply waiting for the equipment to arrive. It came down to lead times; during that stretch there was nothing on our side to do except wait. Consequently it was mostly an absorption effect, and for the full year that was the larger hit. And clearly, we also had some weather and so on. But let me concentrate on Calvert and Hopewell. Calvert was the significant one. That facility is running again and producing — it did affect sales as such, but largely absorption. We are recovering. As for Hopewell, it caused some effect this quarter, yet it is genuinely progressing. Our output rates aren't at the level we'd like. So the plant is running — the budget sits above what we expected, as do the production rates. We aren't making product at the pace we want. So once more, from an absorption standpoint, those are the major effects. Between the 2, I'd put it at roughly 20-ish on the front end, combining weather and Calvert, plus about another $10-ish at the back end from Hopewell, just to keep it very high level regarding certain of those products; so for us this is — to put it plainly, every other area is delivering as we expected. If would have should have could have, but $30 million is an internal matter, and it doesn't reflect some of these — our broader core performance. So all in all, this ought to have been a far stronger year; we're extremely frustrated, obviously, as everyone is about how we're operating, yet these are internal matters; we're addressing them. As I mentioned, Calvert is back online, and the resources plus the investments are already in place at Hopewell to restore productivity to where it should be. Another point I'd highlight regarding our EBITDA effect is that we do not intend to do any major inventory rebuild, all right? With the uncertainty we face, our focus right now is on particular product lines. The Calvert City outage actually assisted us in lowering inventories and getting them normalized. Certain products will be built up. In the same way, with the HEC, we accumulated inventories for the Parlin transition, and that's approaching. We will build on particular product lines, yet not across the board. We feel quite good about every change we've implemented regarding timing. We've lowered the company's overall cost structure. To wrap up, we've cut back on running certain units within our BT&D network. That's lowered both our cost structure and how much absorption we require. As a result, in this unpredictable climate, we're in a stronger, steadier position when it comes to the normal production rates we have to run. So these are particular plant matters that we're working through right now. And Jeff, regarding your specific question about Specialty Additives operating income or EBITDA in the back half, one major element of the Hopewell adjustment — the 10 million to 12 that we referenced, material — falls inside Specialty Additives. Given that, my expectation would be Specialty Additives declining versus the prior year.

Jeff Zekauskas analyst
#18

All right. Next, regarding intermediates and solvents, various duties have been imposed on producers based in the U.S. as well as those offshore in Europe. Is there any impact on you? And regarding how much EBIT or EBITDA I&S brings in, what does the path ahead look like? Are things heading lower, higher, or is it simply unknowable?

Guillermo Novo executive
#19

Jeff, I'd offer 2 points; I'd separate our back integration, which ties to BDO, from how competitors behave. BDO costs are climbing for China's production as a whole; therefore we'd anticipate that, if you examine our — our purpose in this business is supporting VP&D back integration, and that ought to be helped by the competitive landscape since cost structures across Europe and Asia keep rising; we're largely U.S.-based, using natural gas and butane. That puts us in a strong spot. So for the whole company, that's a positive. Looking specifically at intermediates, we don't move much BDO. Derivatives matter more. We're observing pricing. For several quarters now, the business has been running steadily at the trough, the trough, yet it's steady. What I see as the current problem is that with price inflation arriving, some gains will follow. With any luck, because our cost structure is lower, that could be an upside opportunity. Only today, Alessandro brought up the <<inaudible>> BDO figures. So across the U.S., prices are rising, 5% to 6%; thus there's solid momentum behind it. Still, I'm not sure whether there's anything more you'd want to add, Alessandra.

Alessandra Assis executive
#20

Yeah. No, that is correct. We put out word about price hikes this month that we're in the process of rolling out. And Thermo, like you said, the way costs hit us differs between the U.S. and China. We're also seeing the market settle down, with less price erosion happening. With those cost effects coming through, prices have begun climbing. Yet supply remains — it's essentially the case that this market looks different compared with other markets that are — other segments, you know, getting hit by the Middle East conflict. So certainly, despite costs rising, supply-demand dynamics are still in play, and availability hasn't taken much of a hit. In this market, availability isn't shifting much because of the Middle East conflict. So we're proceeding with the price hikes, while obviously keeping the supply-demand dynamics in check.

Executive executive
#21

And Jeff, regarding margins, at Lima we reduced the pace there since it supports Calvert City — clearly, what happens at Lima affects Calvert City. That's why we had to cut back. So absorption did take a hit from this; however, everything is settling down now that Calvert City is ramping up. As a result, going ahead, the cost picture ought to look more typical.

Mike Sison analyst
#22

I'm just interested in your perspective on 2027 — I realize it's a bit soon to provide detailed guidance. But just in terms of direction, what should the run rate look like? And what headwinds ought we to anticipate in the coming year?

Guillermo Novo executive
#23

Mike, I'll start at a high level, and then, William, feel free to add anything else. What I mean is, we aren't prepared to discuss 2027 yet, but broadly speaking, here's what we're observing at present. Naturally, macro uncertainty is on everyone's mind. None of us can predict the future. Still, I'd say looking at this year, the business mix — we've completed all the necessary work. It's delivering exactly as we anticipated. Every one of the businesses — clearly, Life Science and Personal Care — is resilient. So we'd anticipate that pattern to persist. Specialty Additives is holding steady. I believe we're picking up volume. Take coatings, for instance — this year, we'll achieve volume growth for the full year, and that's tied to share and re-entering the market. I feel really positive about what Dago and the team are accomplishing. The reaction now is a far more premium reaction in the marketplace. We're introducing many products at varying price points. So we aren't merely cutting price; we're offering customers, hey, options at different price points for what we can deliver. We can stay competitive; we can alter cost performance. So I feel SA is positioned well to keep driving share gain; and clearly, the expectation would be — the bigger question is whether North America and Europe will begin to improve; we don't see China getting much better in the foreseeable future when it comes to macro demand on the construction side. We've streamlined the manufacturing. I'll say it again, this has been a tough year with internal operating issues, but our cost structure, the footprint changes, all of that makes us stronger, more competitive, and we have a lower cost base. So that ought to keep eliminating a lot of these issues we had this year, and that should add to next year's performance. It should have added to this year's performance. The Globalize and Innovate efforts keep up good momentum. So we'll keep working on that. Then we keep enhancing our systems and processes to provide more visibility to our regional management teams as they begin driving their P&L. We're delegating many of these activities to the front line so they can take greater ownership and accountability for driving performance. So our goals going forward stay the same — if you look at the 5 5% growth, that's a target overall for the market, plus or minus a few percentage points, returning to the 25% EBITDA margins and 55% free cash flow conversion. And Mike, we don't want to get into — we don't want to be premature about getting into the specifics on '27, but just a few things to keep in mind that we spoke to. To begin with, during the opening six months of this year at VLO — correct — we had the outage, the extension, plus weather, and those together created a $20 million effect in that first half. Secondly, our team keeps performing at a high level; naturally we're paying close attention to <<inaudible>>, since it falls short of what we expect, yet BP&D along with the small plant consolidation — every bit of that effort is moving forward. As a result, you should keep anticipating some carryover gain from it. At Hopewell, the team is putting in the work. We're dedicated to making operations better, especially during the latter half of this year. We'll begin seeing a bit of sequential carryover advantage as we head into fiscal '27. Naturally, price raws make this quite fluid. Still, at present, that's clearly a major component of next year's carryover — certain pricing actions and raw material too. Then, as Guillermo mentioned, there's the contribution from volume growth and the mix improvement eventually as we push toward globalizing and innovating. And truly, the sole item on the other side, naturally, is that cost inflation has to be handled. So I'd say multiple factors suggest a solid rebound as we move into fiscal '27, and much of that rests within our own control.

Steven Haynes analyst
#24

I'd like to revisit the relationship between pricing and costs briefly. Could you sharpen the picture of how much price improvement you anticipate relative to the amount costs are climbing? I'm only a bit — and apologies if this came up before in today's call — but does the guidance midpoint treat that as a wash for this year? Or do you see it landing as net positive or net negative? Sharpening that whole picture would really help.

Guillermo Novo executive
#25

Thank you, Steven. That's a solid question and a significant one; so let me begin by grounding things in what was already stated during the call, then I'll layer on some further detail; the favorable piece for us, correct, is that we bought quite a few of our raws originating from the U.S., correct? And therefore even the ones that consume lots of energy or come from petchem, much of that originates in the U.S; and consequently the method we've used to size this centers on percent of sales, simply to assist your framework. So on the whole, we combine energy-intensive raws along with petchem linked raw materials and freight since freight clearly is moving too. That comes to approximately 20% of sales. 15% is the raw material basket, 5% is freight, so 20% overall. So despite our strong positioning, we're, naturally, not shielded from global volatility. Several of our processing inputs have risen, naturally, and that shifts considerably across product line and region. So if you separate out that 20% exposure of sales and suppose it's up 10% to 15%, you'll get a sense of the increase that we're seeing on the cost structure. As you surely understand, there are lagged elements, both in pricing and raws. On the raws side, I'd note the lag runs somewhat longer; thus you do receive some favorable raw price benefit during the second half on that basis thanks to our inventory position. But I'd say the truly key piece for us, given that magnitude, 10% to 15% on that 20% of sales, is that the team considers it a manageable exposure for us, and one we can manage to cover; and on the whole, I mean, we're discussing — you could take 20%, attach an inflation figure to it. That's raw material, we're within single digits; we've announced — it varies by region. Certain product lines run far higher. So I don't wish to generalize, but 3% to 8% generally has been roughly the figures we've provided, I'd say, if I average out some of those figures; we don't want to get into specific. Conversations with our customers are ongoing, along with those details, yet that figure is quite achievable on our end, and our history of pushing that forward has been solid.

Chris Parkinson analyst
#26

Let me ask something broad. Looking worldwide at essentially all of your rivals — and I realize this space is quite fragmented — but in VP&D, in cellulose, in HEC, basically each and every supplier has pushed prices up. I'm somewhat puzzled by the mismatch regarding customer acceptance, or maybe I should say acceptance that hasn't fully arrived, since it appears nobody is actually planning for it in their budgets around the midpoint of this year. Meanwhile, in some regions, folks could even confront shortages given that supply availability is quite tight at the moment. So what are you truly hearing from buyers? Is it a matter of when rather than if? Or how would you describe the situation as we head toward midyear?

Guillermo Novo executive
#27

I wouldn't call it an if. Things are in motion. As I mentioned, we're advancing on all fronts. Everyone grasps the dynamics at play, and we're making progress. So we aren't doubting whether we need to price or whether we can. That's underway, and we anticipate it will pay off. What we want to ensure everyone grasps is that our petrochemical exposure is lower. Thus our figures represent the necessity; our margin growth doesn't come from pushing prices higher in an environment like this. We aim to recover our inflation, our margins, so erosion doesn't set in; and I believe our customers realize that; yet our overall margin results stem from value pricing and from controlling our cost structure. And value pricing is proceeding quite well, particularly when you consider certain newer products. The price increase related to inflation is going quite well. Clearly, this year we've implemented many strategic cost actions, but that's the area where I'd say we fell short internally with 2 of the plants.

Chris Parkinson analyst
#28

And then only as a really fast second question, only within personal care, near the start of the year — I would say the finish of '25 going into '26 — there had been a bit of chatter regarding inventory destocking in certain places. Meanwhile, it does appear that you are witnessing rather meaningful gains, particularly within a few of the biofunctionals. What are you picking up from customers concerning the remaining portion of the year when it comes to end market demand and inventory management? It looks like everything is back on track, but how confident are you about that?

Guillermo Novo executive
#29

Chris, do you want to weigh in, so during Q1, during the December quarter, as we said, once you exclude a few of those particular customer outages, we had risen by low single digit, and momentum is still showing up for us this quarter since we're up low to mid-single digits. I would break that apart into 2 pieces. You have the base, and then you have the actions that we are pushing. So when you examine our biofunctional actives, the base keeps delivering strong results. And we've enjoyed truly strong success broadening our customer base and having our new products taken up and ramped with customers. Likewise, microbial protection — the base is holding up nicely, and the team has done an absolutely outstanding job converting our pipeline and carrying on with share gains in that business line. And even our care ingredients, which was the one hit by the customer outages during Q1 — they're back online, and that will keep flowing through the balance of the year. So as we look ahead across the rest of the year, we see the market staying comparatively stable. There are the things we are driving within our globalized business lines that we expect will keep flowing through. And then we'll keep watching how the base performs across the balance of the year since it is dynamic, even though we still see demand that is fairly robust.

David Begleiter analyst
#30

Guillermo, regarding that price-versus-cost fill in fiscal Q3, what size of a tailwind does that dynamic represent? And what should we also expect for fiscal Q4? What amount of a dollar EBITDA tailwind do you anticipate price loss will provide for you folks in fiscal Q3 and beyond?

Guillermo Novo executive
#31

So I'd say, when it comes to pricing and raw materials, the inflation, the bulk of it is going to begin affecting us somewhat later. So the challenge on our end is aligning the pricing. The costs, you know, are rising, and for the time being they'll move through into our inventories. But we need to be certain that we get our costs — our pricing set up so it covers that as we go forward. So specifics regarding the price hikes and how they flow through, we haven't truly laid those out, but that's already beginning to arrive this month, and it's accumulating. So as we go forward, we'll report more; but it's largely a matter of timing; we do — I'd say, in the spot business, I believe we'll be shifting spot non-contract business, and we'll shift that more quickly. I think a great deal of contract business is on our books, particularly when you look at pharma along with some of our larger customers. And that's where the timing is something we're working through with them. But the magnitude of the increase we're obtaining right now — we're not uncertain about it. Still, at this point in time, a specific number isn't something we can give you.

David Begleiter analyst
#32

Great. Regarding the updated EBITDA guidance, did incentive compensation accruals change for this year?

Guillermo Novo executive
#33

Nothing major. The main problem, I'd say, involves Specialty Additives. Clearly, operating difficulties had some effect, and we're addressing that, yet overall it isn't a big impact, since across most of the company, incentive comp works on a business-by-business basis.

John Roberts analyst
#34

What's the engineering root cause behind the ramp-up problems at Hopewell? Are you handling things there in a different way compared with other HEC locations?

Guillermo Novo executive
#35

Yes. Keep in mind that with Hopewell, the entire problem stems from our shutdown of Berlin. The plant's mix shifted considerably. Late last year we had just added some capacity investments for HEC overall, but what's really pushing productivity is that change in mix. So we're directing a lot of investment toward supporting the new mix. As a result, we are producing — we are getting the products we want, though not at the output rates we were aiming for. That, I believe, is the main problem. Still, the teams are already addressing it. The budgets came in somewhat higher, and that comes down to, I'd say, 2 factors. One involves our own performance. The other is that we're allocating additional resources to push those improvements forward in the near term.

David Begleiter analyst
#36

Moving on to Personal Care — growth there ranged from high single digits in skin care down to low single digit for Oral Care and Home Care. Does skin care simply have more innovation behind it, or could comparisons be another factor creating that unevenness?

Guillermo Novo executive
#37

I'll start at a high level, then Jim may want to add something. It really comes down to which product line you look at. Clearly, a great deal of the biofunctional actives — micro included — flows into skin care and those categories. So product mix plays a role. The base business matters too, though Jim can offer additional detail, particularly regarding the base business. Jim: Sure, happy to. John, like you said, much of our innovation along with our globalized businesses centers on both skin and hair, which together make up most of our Personal Care business, and both of those segments are growing quite nicely; with Oral Care, we've also — and this should come as no shock, we've mentioned it before — occasionally had order pattern timing. So once again this year we're seeing some shift in order pattern timing, which is fine for the full year. That's what's behind some of the perhaps lower comps versus the prior year. You'll observe that step up as we move through the rest of the year in oral.

Mike Harrison analyst
#38

I wanted to ask about Life Sciences. During the previous period when supply chains got disrupted and we saw that kind of inflationary cycle, your company managed to gain a bit of market share, sort of on a temporary basis, in pharma, and afterward it went back to where it had been. I'm just wondering whether that same type of dynamic might show up again, considering perhaps some of the difficulties your rivals are facing in Europe and Asia. And what would you do differently so that you're getting share gains that last longer with certain customers?

Guillermo Novo executive
#39

Mike, let me give you the big picture, and Alessandro, jump in if you have anything particular, but just broadly speaking. At this degree of uncertainty with the war, everything we're hearing and reading would suggest, hey, if this keeps going, then cost structures for China or Asia overall, and India too, would get affected, and for Europe they would rise as well. So from the Western world, we're among the few big manufacturers in that product line, and our base is the U.S. At our scale, there isn't much other output in the U.S. Our competitors mostly sit either in Europe or in China. So an opportunity exists. As Alessandra mentioned, at this moment there isn't a shortage. So cost wouldn't be the problem. What I think would matter more is availability, particularly for Europe and for China; so an opportunity could develop as things progress. What would we do about it? Clearly, first, this risk drives home to customers how much they need balance when it comes to their supplier base, and having that balance plus a U.S. base with good energy costs and a good cost-structure position is plainly a helpful reminder for everyone, and I believe that works in our favor. But clearly, if that scenario begins to unfold, there are steps we could take regarding contracts and how we choose to handle it; yet I think the key thing is we would also be very upfront with everyone about which of these share shifts are permanent and which would be temporary; and — but as orders arrive we would get the most out of our performance; but if you want to — is there anything else you'd add?

Executive executive
#40

Absolutely. Like Guillermo said, right now there isn't any scarcity, yet what we're noticing is that we hold the biggest — actually the widest-ranging excipient portfolio anywhere in the pharmaceutical sector. Our supply is dependable and top quality. So without question, over the past month we've observed customers feeling uneasy regarding their business continuity planning, their BCP efforts, and exploring dual sourcing. That creates chances in places where previously we had no involvement. So certainly, we view this as — opportunities do exist. And just as Guillermo noted, shifting more of this toward longer-term arrangements in terms of agreements; yet for sure, we anticipate life sciences, and pharma in particular, will keep producing solid growth during the back half of the year, and moving ahead, we recognize how resilient pharma demand is, and we're essentially focused on seizing the momentum behind our globalized Innovate, which are the areas where chances exist to expand our market share. So certainly, with the disruption, no shortage is apparent to us, but it does create opportunities for us from — as our customers continue working on their BCP plans.

Guillermo Novo executive
#41

To wrap up, Mike, regarding what you said — and this goes beyond only the VP&D matter. What I mean is, uncertainty is widespread; and based on how events unfold, substantial upside could emerge in intermediates, meaning shortages. Should conditions deteriorate, significant upside exists. None of us can predict the future; we don't believe it's wise simply to take an excessively bullish stance in the guidance we're providing, particularly regarding revenue and the core businesses, the core performance of the business portfolio. Our view is that we have solid growth, solid momentum, and we don't want to be too optimistic and then get caught off guard on that part of things, and we're being open about that. On the EBITDA side, I'd say the same. Should that improve, it will lead to higher EBITDA. But once again, we're going to lean conservative. I think we're owning up to our internal challenges, but we want to be — we're extremely happy with all the wider external macro matters. And we do acknowledge that upside exists on pricing impact and that upside exists on — should demand tightness grow.

John McNulty analyst
#42

I'd like to go back to what you said about the innovation side of your midyear progress. My understanding is that you were aiming at $15 million for the full year, and you've already hit $16 million. I believe sales came to $6 million in Q1, which implies $10 million in Q2. So it's obvious that results are arriving better than you'd anticipated, and you're on a trajectory that could wind up at twice the original target. Could you help us frame where you think the year will finish in run-rate terms, so we can gauge how that innovation might fuel growth as we head toward 2027?

Guillermo Novo executive
#43

The picture you painted is basically how we view it too. This is a cumulative metric, after all, for the whole year. So if the business is already won and sitting at a given run rate, and that holds, then we'll keep performing at that level — that's roughly what we expect. Just to remind you, from a dollar standpoint, a great deal of it comes from the core innovations we've been pursuing, and the growth is extremely healthy, with pharma and personal care, I'd say, driving much of it at present. We're also rolling out plenty of new products. So I think there are opportunities for momentum to continue, with the core in the near term. And I'd point out that I'm quite excited about how the team is progressing on some new platforms in major projects, whether in personal — particularly personal care — and Specialty Additives. In Life Science, it would be more ag pharma, which has a longer pipeline. So those things will need somewhat more time before they take off. But with all of them, we're truly confident — we've demonstrated the technical and performance value of these platforms. The teams are now heavily focused on product development and specific customer projects to adapt the technologies to their needs. So in the near term, and even more crucially over the long term, we foresee momentum continuing there.

Guillermo Novo executive
#44

Thank you all for spending time with us and for the interest you've shown. I just want to restate the three key messages we shared. On the business front, we feel very good about how the businesses are performing overall and about the market trends — whether that's life science holding up resiliently, personal care remaining steady, specialty additives building momentum as we pick up share, Intermediates sitting stable at the trough with chances to get better depending on how the market moves, or globalize and innovate, which is very strong. The competitive dynamics have been — and still are — strong, yet stable. That gives us the space to genuinely begin pushing our own agenda going forward. And we have not observed any meaningful prebuying of our products. So all in all, the business side is tracking probably on the stronger end of what we expected. We're taking pricing action, and there's upside when it comes to the financial impact there; we're tempering that somewhat, simply out of caution about the demand outlook in core markets, since we don't own a crystal ball and we aren't seeing an immediate recovery. Coatings, North America, Europe is a prime example. So we're taking our cue from our customers and from what they're telling us. And finally, the genuine driver behind the changes to our outlook is more about our operating performance and our manufacturing — three issues that have hit us, and two of them are now behind us. Calvert City, the equipment failure along with the delays in obtaining the replacement equipment, which hurt our absorption, plus weather impacts. And at this moment, our big focus is Hopewell and restoring its productivity. That part of the performance frustrates us, but we're working on it; it's within our control. It isn't a reflection of the wider portfolio or of all the larger strategic actions, and we're confident we'll get past it in the near future; so thank you for your time. We look forward to connecting with you afterward and answering any other questions you may have.

Operator operator
#45

We appreciate everyone joining us on this call today. That brings the session to a close, and you're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ashland Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Ashland Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.